Stock Notes

Divi's Laboratories

Every Finvezto stock note on Divi's Laboratories, dated and newest first. Coverage spans pharma.

1 note and counting
07 Nov 2026
Divi's Laboratories' Q2 consolidated profit rose 64% to Rs 1,127 crore as revenue grew 35% to Rs 3,676 crore.
Profit before tax rose 65% to Rs 1,505 crore with no exceptional items, so the jump came from operations. Year-ago quarterly profit was Rs 689 crore.
Finvezto Membership

Get the research behind the notes

Stock notes are the free daily layer. The membership carries the full Flexi-Wealth system: an ETF core portfolio with monthly rebalancing signals, fifteen quality-momentum stocks with exact weightages every month, options income and hedging recommendations, and the institutional data toolkit. One flat membership covers everything.

Become a Member Read free sample research →

Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630. Stock notes are market commentary for general information and education. They are not investment advice, not a recommendation to buy or sell, and do not account for any individual's financial situation. Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Past performance is not a guarantee of future results.